Taken together, these findings strongly suggest the involvement of VEGFR signaling pathways in melanoma and support the hypothesis that VEGF-targeted antiangiogenesis therapy (AAT) may prove to be effective either alone or in combination with other therapies. This evidence concerns the gene VEGFA and melanoma.